Key result
Switching anticoagulants demands tailored bleeding and thromboembolic risk assessment alongside drug pharmacokinetic profiles.
Why the study?
Switching between various anticoagulants is common in clinical practice, but guidance on risk assessment and pharmacokinetic considerations for optimal switching is needed.
Provides general principles and considerations for safely switching between different classes of anticoagulants in clinical practice.
Answers are grounded in this paper and cite their sources.
Supports individualized bridging in anticoagulant switches; leaves open need for prospective trials to refine protocols.
Anticoagulant therapy has long been the gold standard therapy for stroke and/or systemic embolic prevention and treatment. Anticoagulants generally include parenteral anticoagulants that are extensively used in acute situations for an immediate anticoagulant effect, and oral anticoagulants which are used for long-term therapy. Warfarin has been one of the only oral anticoagulants available during in the past 60 years. In recent years, a new generation of oral anticoagulants has been introduced which is challenging thromboembolic prevention and treatment. Switching to and from various anticoagulants are common situations in clinical practices. Individual’s thromboembolic and bleeding risk assessment should be assessed before switching. Moreover, the pharmacokinetic profile of each anticoagulant is also important to guide the best way for anticoagulant switching. For example, patients with a high thromboembolic risk or patients who switch to warfarin that have a slow onset should be given a parenteral anticoagulant for bridging therapy to prevent thromboembolic events. However, the initial bolus of heparin may be omitted for transitioning to heparin infusion in patients with a high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Junporn Kongwatcharapong (2018) conducted a review in Thromboembolic prevention and treatment. Anticoagulant switching was evaluated. Switching between anticoagulants requires individual thromboembolic and bleeding risk assessment and consideration of pharmacokinetic profiles to guide safe transitions.
Synapse has enriched 10 related papers. Consider them for comparative context: